Myeloid Profiler Next Panel

What is the Myeloid Profiler Next Panel test?

The Myeloid Profiler Next Panel is an advanced molecular genetic test used to detect

mutations associated with myeloid blood cancers and haematological disorders. The test uses next-generation sequencing (NGS) technology to analyse multiple clinically important genes simultaneously.

It helps in the diagnosis, prognosis, and treatment planning of myeloid malignancies.

Why is the Myeloid Profiler Next Panel test done?

• To identify genetic mutations linked to myeloid
• To support diagnosis of leukemia and related blood

 

• To guide targeted therapy and personalized cancer
• To assess disease prognosis and risk
• To monitor disease progression and treatment

Who should get tested for the Myeloid Profiler Next Panel test?

• Patients with suspected or confirmed myeloid
• Individuals with abnormal blood counts or bone marrow
• Leukemia patients requiring genetic
• Patients advised for precision oncology

More about the Myeloid Profiler Next Panel test

This comprehensive genomic profiling test evaluates multiple cancer-related genes associated with Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), and other myeloid neoplasms. The results help clinicians make informed decisions regarding targeted therapy and disease management.

Other/Similar names of the test

• Myeloid NGS Panel
• Myeloid Mutation Profiling Test
• Leukemia Genetic Panel
• Haematology Genomic Profiling Test